Companies: 10,795·Total market cap: $144.5T
Helix BioMedix, Inc.

Helix BioMedix, Inc.

HXBMOTCHealthcare● Active
$1.79
+$0.00(+0.00%)
Market Cap$402227
P/E Ratio
52W High$6.45
52W Low$1
Overview

Helix BioMedix, Inc.(HXBM)股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · HXBM · 截至 Jun 9, 2026

关键指标

EPS (TTM)hxbm eps ttm · hxbm earnings per shareEarnings history
PE Ratio (TTM)hxbm pe ratio ttm · hxbm price to earningsPE Ratio deep dive
Revenue (TTM)hxbm revenue ttm · hxbm annual revenueFull revenue history
Dividend Yield不分红does hxbm pay dividends · hxbm dividend yieldDividend history
Shares Outstanding224,707hxbm shares outstanding · hxbm floatShares outstanding history
Next EarningsTBAhxbm earnings date · hxbm next earningsEarnings history

财务快照

完整财报
FY 2025Revenue$807193.00▲ +0.37% YoY
202320242025
helix biomedix, inc. revenue · hxbm revenue 2025
FY 2025Net Income-$551512.00▲ +43.86% YoY
202320242025
helix biomedix, inc. net income · hxbm profit 2025
FY 2025EPS$-2.45▲ +43.94% YoY
202320242025
hxbm eps · helix biomedix, inc. earnings per share 2025

股票表现

完整历史
1D+0.00%
1W+0.00%
1M+0.00%
3M+5.29%
YTD-10.50%
1Y-75.07%
5Y-92.78%

关于 Helix BioMedix, Inc.

CEORobin L. Carmichael
IPO DateMar 25, 1999
Employees8
CountryUS

Helix BioMedix, Inc. is a U.S.-based enterprise specializing in skin health, focusing on advanced dermatology and consumer-oriented product lines. The company's primary activity involves creating and …

what is helix biomedix, inc. · hxbm stock overview · helix biomedix, inc. company profile · who is helix biomedix, inc. ceo · hxbm OTC · helix biomedix, inc. headquarters · helix biomedix, inc. business segments

关于股票概览与关键数据

Helix BioMedix, Inc.(HXBM)是 Biotechnology 行业的 Healthcare 类公司,于 Mar 25, 1999 在 OTC 上市。截至最近交易日,HXBM 股价为 $1.79,市值约为 $402,227。过去12个月累计回报 -75.07%,年初至今回报 -10.50%。

2025 财年 Helix BioMedix, Inc. 营收 $807193.00。完整财务数据(营收历史、盈利、资产负债表)请使用上方标签页。

常见问题

截至最近一个交易日,Helix BioMedix, Inc.(HXBM)股价为 $1.79,在 OTC 上市,52周区间为 $1.00 – $6.45。

HXBM 最新股价HXBM quote todaylive ticker 实时行情
数据来源:Financial Modeling Prep最后更新:Jun 9, 2026本内容不构成投资建议